VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Lags Revenue Estimates
VTGNVistaGen Therapeutics(VTGN) ZACKS·2024-08-14 06:30

VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of 0.35pershareversustheZacksConsensusEstimateofalossof0.35 per share versus the Zacks Consensus Estimate of a loss of 0.41. This compares to loss of 0.94pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof14.630.94 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 14.63%. A quarter ago, it was expected that this company would post a loss of 0.34 per share when it actually produced a loss of $0.25, delivering a surprise of 26.47%.Over the last four quarters, the company ...